Cancer · 2022 · 55 citations · 19 references
MedicineOncologyPharmacotherapyChemotherapyImmunotherapyMedical OncologyBiliary Tract CancerCancer ImmunotherapyCheckpoint Inhibitor TherapyCombination ChemotherapyCombination ImmunotherapyImmune Checkpoint InhibitorsCytotoxic T Lymphocyte - Associated Protein 4 PathwayCytotoxic T-lymphocyte-associated Protein 4 InhibitorsCytotoxic T-lymphocyte-associated Protein 4 PathwayCytotoxic T-lymphocyte-associated Protein 4 RegulationDual Checkpoint InhibitionProgrammed Cell Death Protein 1 InhibitorsProgrammed Death-ligand 1 InhibitorsTumor-associated Antigen Targeting
BACKGROUND: Gemcitabine and cisplatin has limited benefit as treatment for advanced biliary tract cancer (BTC). The addition of an anti-programmed death receptor (PD-1)/PD-ligand (L1) antibody to either systemic chemotherapy or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) antibody has shown benefit in multiple solid tumors. METHODS: In this phase 2 trial, patients 18 years or older with advanced BTC without prior systemic therapy and Eastern Cooperative Oncology Group Performance Status 0-1 were randomized across six academic centers. Patients in Arm A received nivolumab (360 mg) on day 1 along with gemcitabine and cisplatin on days 1 and 8 every 3 weeks for 6 months followed by nivolumab (240 mg) every 2 weeks. Patients in Arm B received nivolumab (240 mg) every 2 weeks and ipilimumab (1 mg/kg) every 6 weeks. RESULTS: Of 75 randomized patients, 68 received therapy (Arm A = 35, Arm B = 33); 51.5% women with a median age of 62.5 years. The observed primary outcome of 6-month progression-free survival (PFS) rates in the evaluable population was 59.4% in Arm A and 21.2% in Arm B. The median PFS and overall survival (OS) in Arm A were 6.6 and 10.6 months, and in Arm B 3.9 and 8.2 months, respectively, in patients who received any treatment. The most common treatment-related grade 3 or higher hematologic adverse event was neutropenia in 34.3% (Arm A) and nonhematologic adverse events were fatigue (8.6% Arm A) and elevated transaminases (9.1% Arm B). CONCLUSIONS: The addition of nivolumab to chemotherapy or ipilimumab did not improve 6-month PFS. Although median OS was less than 12 months in both arms, the high OS rate at 2 years in Arm A suggests benefit in a small cohort of patients.
19
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2015 · 8.1K citations · Full text
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn, Shukui Qin, Masafumi Ikeda et al. · New England Journal of Medicine · 2020 · 7.2K citations · Full text
Medicine, Oncology, Pharmacotherapy +12
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Juan W. Valle, Harpreet Wasan, Daniel H. Palmer et al. · New England Journal of Medicine · 2010 · 4.4K citations · Full text
Medicine, Oncology, Pharmacology +12
Yelena Y. Janjigian, Kohei Shitara, Markus Moehler et al. · The Lancet · 2021 · 2.9K citations · Full text
Medicine, Oncology, Pharmacotherapy +16